Skip to main content
Premium Trial:

Request an Annual Quote

Moderna Expects Early Trial Data Next Month

Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November, the Washington Post reports.

Moderna started late-stage testing of its candidate SARS-CoV-2 vaccine in July. Its vaccine, dubbed mRNA-1273, is an mRNA-based vaccine that encodes the SARS-CoV-2 spike glycoprotein, and was developed in conjunction with the US National Institutes of Health. Early-stage testing suggested the investigational vaccine could trigger an immune response.

Moderna, as well as Pfizer and AstraZeneca, released their trial protocols in September, and, at that time, Moderna's protocol estimated that it would not be able to determine if its vaccine works until 2021, as the New York Times then noted.

According to the Post, Moderna has now announced that it has fully enrolled its 30,000-individual trial. More than 25,000 people in the trial have received their second dose of the candidate vaccine or placebo, and the company says it should have two months of follow-up data on half the participants by mid-November and suggests that that early data could give an indication of whether or not its vaccine provides protection, the Post adds.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.